Serum levels of soluble Fas in patients with Graves’ ophthalmopathy

Kenji Ohtsuka, Masato Hashimoto

Abstract
Aim—To assess levels of soluble Fas (sFas) in the sera of patients with Graves’ ophthalmopathy.

Methods—The subjects in this study were 43 patients with Graves’ ophthalmopathy and 11 normal subjects. Serum levels of sFas were determined by sandwich enzyme linked immunosorbent assay. In addition, serum levels of thyroid stimulating antibody (TSAB) were also measured in all the patients.

Results—The mean serum level of sFas was 1.35 (SD 2.03) ng/ml in patients with Graves’ ophthalmopathy, and 0.93 (0.32) ng/ml in normal subjects. Serum levels of sFas in the subgroup of 24 patients with diplopia (1.98 (2.56) ng/ml) were significantly higher than those in the subgroup of 19 patients without diplopia (0.56 (0.24) ng/ml) and normal subjects (p <0.001). Serum levels of sFas in the subgroup of 27 patients with extracocular muscle hypertrophy (1.81 (2.46) ng/ml) were significantly higher than those in the subgroup of 16 patients without extracocular muscle hypertrophy (0.58 (0.26) ng/ml) among the patients with Graves’ ophthalmopathy and normal subjects (p <0.001). Serum levels of sFas were not significantly different between the subgroup of 24 patients with proptosis (1.15 (0.98) ng/ml) and the subgroup of 19 patients without proptosis (1.61 (2.88)). In contrast, the serum levels of TSAB in the subgroup of patients with proptosis (723% (1161%)) were significantly higher than those in the subgroup of patients without proptosis (194% (122%)) (p <0.05).

Conclusions—Elevated sFas levels were associated with extracocular muscle disorders but not with proptosis. On the other hand, elevated TSAB levels were associated with proptosis but not with extracocular muscle disorders, suggesting different immunological mechanisms for the extracocular muscle disorders and proptosis in Graves’ ophthalmopathy. Determination of the serum levels of sFas and TSAB could provide useful markers for evaluation of the immunological processes involved in the development of Graves’ ophthalmopathy.

Graves’ ophthalmopathy is a chronic autoimmune disorder affecting the retrobulbar tissues and extracocular muscles, and has strong aetiological links with autoimmune thyroid disease. However, not all patients with Graves’ disease develop severe ophthalmopathy.1 2 Some patients never exhibit symptoms of ophthalmopathy even when autoimmune thyroid disease is observed. The mechanisms for the variations in severity of ophthalmopathy associated with Graves’ disease are not known.

Recent studies suggest that retrobulbar fibroblasts are the main target of the immune process in Graves’ ophthalmopathy. Histological examination of retrobulbar tissue samples reveals proliferation of fibroblasts accompanied by accumulation of glycosaminoglycans.3 Connective tissue, fat, and muscles are infiltrated by mononuclear cells, mainly T cells.4 Retrobulbar T cells from patients with Graves’ ophthalmopathy specifically recognise autologous retrobulbar fibroblasts. The presence of autoreactive T cells might be responsible for the induction of ophthalmopathy.

The survival of activated T cells is regulated by different mechanisms. Apoptosis is one of the primary control mechanisms for the negative selection of an immune response. The interaction between the cell surface molecule Fas and its ligand has been proposed as a primary mechanism initiating T cell apoptosis. Defects in the Fas/Fas ligand apoptosis pathway have been shown to result in autoimmune disease in humans.6 Soluble Fas (sFas) molecule, which lacks the transmembrane domain, because of alternative splicing, inhibits Fas mediated apoptosis of T cells. Therefore, elevated serum levels of sFas may be associated with autoimmune diseases, and correlated with the activity of these diseases.8-10 Recently, it has been reported that the serum levels of sFas were increased in patients with Graves’ disease, and that they were correlated with the free thyroxin levels.11 In this study, serum levels of sFas were determined in patients with Graves’ ophthalmopathy, and the relation between the serum sFas levels and the severity of ophthalmopathy were investigated.

Patients and methods
The subjects of our study were 43 consecutive patients (age range 15–74 years; mean 43 years; 33 women, 10 men) with Graves’ ophthalmopathy examined at Sapporo Medical University Hospital between May and September 1998, and 11 normal volunteers (age range 23–51 years; mean 36 years; nine women, two men). We confirmed that each normal volunteer has no symptoms of autoimmune diseases up to the present. Informed consent was obtained from all the subjects after the nature of the examination had been explained.

The diagnosis of Graves’ disease was based on history; conventional symptoms of thyro-
toxicosis associated with a diffusely enlarged goitre; elevated levels of serum T3, free T3, T4, and free T4; suppression of the serum thyroid stimulating hormone (TSH); and increased thyroid 131I uptake. Elevated antithyroid stimulating antibody (TSAB), antithyroglobulin antibody (TGAB), and antithyroid peroxidase antibody (TPOAB) titres or the presence of ophthalmopathy provided supporting evidence for the diagnosis.

A complete eye examination, including applanation tonometry, exophthalmometry, and measurement of eye movements, were performed by one ophthalmologist at the first visit before any systemic medical treatments in all the patients. Serum samples were stored at −80°C for later determination of sFas levels. Serum levels of TSAB, antithyroglobulin antibody, and antithyroid peroxidase antibody were also measured in all the patients. Coronal and axial computed tomographic scans of the orbit were performed in all 43 patients, and the thickness of the extraocular muscles and proptosis were measured. All patients were classified in three different ways depending on the presence or absence of diplopia, presence or absence of extraocular muscle hypertrophy, and presence or absence of severe proptosis. Diplopia was defined as double vision in any eye positions in the red glass test. Extraocular muscle hypertrophy was defined as thickness of any of the rectus muscles more than the diameter of the optic nerve in coronal computed tomographic scans. The criterion for diagnosis of proptosis was defined according to an exophthalmometry result of ≥19 mm or a 3 mm difference in between the two eyes.

Serum levels of sFas were determined by sandwich enzyme linked immunosorbent assay with a sFas ELISA kit (MBL, Nagoya, Japan). The detection limit was 0.01 ng/ml with an intra-assay coefficient of variation of 3.9% and interassay coefficient of variation of 3.8%. Serum samples were tested at a dilution of 1:5. Serum levels of TSAB were determined using porcine thyroid cells. A crude γ globulin fraction obtained from sera by the polyethylene glycol precipitation method was used for the assay of TSAB. The serum sample of each patient was tested twice, and the average was used to denote the serum levels of sFas and TSAB in a given patient. The serum levels of sFas and TSAB in the subgroups were compared by the Mann–Whitney U test.

Results

The mean serum level of sFas was 1.35 (SD 2.03) ng/ml (n = 43) in patients with Graves’ disease and 0.93 (0.32) ng/ml (n = 11) in normal subjects. The serum levels of sFas in patients with Graves’ disease were not significantly higher than those in normal subjects. However, the serum levels of sFas in the subgroup of patients with diplopia (1.98 (2.56) ng/ml, n = 24) were significantly higher than those in both the subgroup of patients without diplopia (0.56 (0.24) ng/ml, n = 19) (Fig 1) and in normal subjects (p <0.001). The serum levels of sFas in the subgroup of patients with extraocular muscle hypertrophy (1.81 (2.46) ng/ml, n = 27) were significantly higher than those in both the subgroup of patients without extraocular muscle hypertrophy (0.58 (0.26) ng/ml, n = 16) (Fig 1) and in normal subjects (p <0.001). On the other hand, the serum levels of sFas in the subgroups of patients with neither diplopia nor extraocular muscle hypertrophy were significantly lower than those in normal subjects (p <0.001).

The mean exophthalmometry measurement value was 19.21 (2.78) mm in the subgroup of patients with proptosis (n = 24) and 14.47 (3.08) mm in the subgroup of patients without proptosis (n = 19). The serum levels of sFas were not significantly different between patients with proptosis (1.15 (0.98) ng/ml) and patients without proptosis (1.61 (2.88)) (Fig 1).

In contrast, the serum levels of TSAB in patients with proptosis (723% (1161%)) were significantly higher than those in patients without proptosis (194% (122%)) (p <0.05), while they were not significantly different between patients with and without diplopia and between patients with and without extraocular muscle hypertrophy (Fig 2). The serum levels of sFas were not correlated with the serum titres of TSAB, TGAB, or TPOAB (Fig 3).
sFas in Graves’ ophthalmopathy

Production of glycosaminoglycan by the cells as a result of an inflammatory process, can result in the fibroblasts. Cytokines, produced by T cells, specifically recognise autologous retrobulbar fibroblasts. Therefore, it is possible that high serum titres of TSAB are related to the development of extraocular muscle disorders.

High serum levels of sFas block Fas/Fas ligand-mediated apoptosis of T cells. Previous studies suggest that autoreactive T cells are involved in the development of Graves’ ophthalmopathy. T cells in the retrobulbar tissue from patients with Graves’ ophthalmopathy specifically recognise autologous retrobulbar fibroblasts. Cytokines, produced by T cells as a result of an inflammatory process, can enhance the proliferation of fibroblasts and production of glycosaminoglycan by the fibroblasts. This may contribute to the pathogenesis of extraocular muscle disorders in Graves’ disease. Therefore, it is possible that sFas is responsible for the induction of extraocular muscle disorders.

The serum levels of sFas in the subgroups of patients with neither diplopia nor extraocular muscle hypertrophy were significantly lower than those in normal subjects. Immunological mechanisms for this are not known. However, it is possible that suppression of serum sFas levels prevents the development of extraocular muscle disorders by facilitating Fas/Fas ligand-mediated apoptosis of T cells.

In contrast, the serum levels of sFas were not associated with the severity of proptosis. However, the serum titres of TSAB were significantly higher in patients with severe proptosis. TSAB is involved in the pathogenesis of autoimmune thyroid disease. Whether or not TSAB has any role in the development of Graves’ ophthalmopathy is not known. Clinically, while no clear correlation has been established between the presence of TSAB and the presence of Graves’ ophthalmopathy, it has been reported that severe ophthalmopathy tends to develop in the presence of high titres in the serum TSAB. The results in the present study were compatible with the results of these studies. Although the immunological role of TSAB in the development of ophthalmopathy is unknown, TSH receptors exist in retrobulbar tissues, including fibroblasts, and IgGs from patients with Graves’ disease stimulate collagen synthesis by fibroblasts. It is possible that high serum titres of TSAB are related to the development of exophthalmos.

Discussion

The serum levels of sFas determined in our study are comparable with the results reported in a previous study of Graves’ disease. The serum levels of sFas were significantly correlated with the severity of diplopia and extraocular muscle hypertrophy, both of which reflect the severity of the extraocular muscle disorders in Graves’ disease.

The results in the present study are compatible with the results of a previous study of Graves’ disease. In that study, the serum levels of sFas determined in our study were significantly correlated with the severity of diplopia and extraocular muscle hypertrophy, both of which reflect the severity of the extraocular muscle disorders in Graves’ disease.

Figure 3 Relations between sFas levels and titres of TSAB (A), TGAB (B), and TPOAB (C).


